autologous plasmablasts
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04284254)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LymphocytesSupplementation
supplementation - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05682144 | Phase 1 | Apr 12, 2023 | Immusoft of CA, Inc. |
| NCT04284254 | Phase 1/Phase 2 (Phase 2) | May 31, 2020 | University of Minnesota |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immusoft of CA, Inc. | For profit | 1 | 1 | 1 | 2023 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1